Between Jan 23 , 2007 , and Sept 19 , 2012 , 592 patients with KRAS exon 2 wild-type tumours were randomly assigned and received treatment ( 297 in the FOLFIRI plus cetuximab group and 295 in the FOLFIRI plus bevacizumab group ) .